ES3033466T3 - Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate - Google Patents
Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylateInfo
- Publication number
- ES3033466T3 ES3033466T3 ES19884611T ES19884611T ES3033466T3 ES 3033466 T3 ES3033466 T3 ES 3033466T3 ES 19884611 T ES19884611 T ES 19884611T ES 19884611 T ES19884611 T ES 19884611T ES 3033466 T3 ES3033466 T3 ES 3033466T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- crystalline form
- type
- compound
- theta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760307P | 2018-11-13 | 2018-11-13 | |
| PCT/IB2019/001199 WO2020099923A1 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3033466T3 true ES3033466T3 (en) | 2025-08-04 |
Family
ID=70732059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19884611T Active ES3033466T3 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220002292A1 (https=) |
| EP (1) | EP3880678B1 (https=) |
| JP (2) | JP2022507251A (https=) |
| CN (1) | CN113302191A (https=) |
| AU (1) | AU2019378161B2 (https=) |
| CA (1) | CA3119711A1 (https=) |
| DK (1) | DK3880678T3 (https=) |
| ES (1) | ES3033466T3 (https=) |
| FI (1) | FI3880678T3 (https=) |
| HR (1) | HRP20250864T1 (https=) |
| HU (1) | HUE071480T2 (https=) |
| IL (1) | IL282996A (https=) |
| LT (1) | LT3880678T (https=) |
| MX (1) | MX2021005424A (https=) |
| PL (1) | PL3880678T3 (https=) |
| PT (1) | PT3880678T (https=) |
| RS (1) | RS66922B1 (https=) |
| SI (1) | SI3880678T1 (https=) |
| SM (1) | SMT202500237T1 (https=) |
| WO (1) | WO2020099923A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL282087B2 (en) * | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| JP7578602B2 (ja) * | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| EP4169921A4 (en) * | 2020-06-29 | 2024-06-19 | Wuhan LL Science and Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2025140586A1 (zh) * | 2023-12-29 | 2025-07-03 | 人福医药集团股份公司 | 一种p2x3受体拮抗剂的固体分散体及其制备工艺 |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2025210540A1 (en) | 2024-04-02 | 2025-10-09 | Assia Chemical Industries Ltd. | Solid state forms of camlipixant and process for preparation thereof |
| WO2026022326A1 (en) * | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
| JP2026049185A (ja) | 2024-09-06 | 2026-03-18 | キヤノン株式会社 | 撮像装置、撮像方法、及びコンピュータプログラム |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3381917T3 (da) * | 2013-01-31 | 2021-10-18 | Bellus Health Cough Inc | Imidazopyridinforbindelser og anvendelser deraf |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
-
2019
- 2019-11-12 HR HRP20250864TT patent/HRP20250864T1/hr unknown
- 2019-11-12 FI FIEP19884611.5T patent/FI3880678T3/fi active
- 2019-11-12 EP EP19884611.5A patent/EP3880678B1/en active Active
- 2019-11-12 CN CN201980088914.9A patent/CN113302191A/zh active Pending
- 2019-11-12 US US17/292,663 patent/US20220002292A1/en active Pending
- 2019-11-12 ES ES19884611T patent/ES3033466T3/es active Active
- 2019-11-12 LT LTEPPCT/IB2019/001199T patent/LT3880678T/lt unknown
- 2019-11-12 PT PT198846115T patent/PT3880678T/pt unknown
- 2019-11-12 JP JP2021525726A patent/JP2022507251A/ja active Pending
- 2019-11-12 SI SI201930943T patent/SI3880678T1/sl unknown
- 2019-11-12 SM SM20250237T patent/SMT202500237T1/it unknown
- 2019-11-12 HU HUE19884611A patent/HUE071480T2/hu unknown
- 2019-11-12 WO PCT/IB2019/001199 patent/WO2020099923A1/en not_active Ceased
- 2019-11-12 CA CA3119711A patent/CA3119711A1/en active Pending
- 2019-11-12 MX MX2021005424A patent/MX2021005424A/es unknown
- 2019-11-12 AU AU2019378161A patent/AU2019378161B2/en active Active
- 2019-11-12 DK DK19884611.5T patent/DK3880678T3/da active
- 2019-11-12 PL PL19884611.5T patent/PL3880678T3/pl unknown
- 2019-11-12 RS RS20250594A patent/RS66922B1/sr unknown
-
2021
- 2021-05-06 IL IL282996A patent/IL282996A/en unknown
-
2024
- 2024-07-05 JP JP2024109053A patent/JP2024153665A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3880678T (pt) | 2025-05-22 |
| MX2021005424A (es) | 2021-06-15 |
| EP3880678A1 (en) | 2021-09-22 |
| CN113302191A (zh) | 2021-08-24 |
| JP2022507251A (ja) | 2022-01-18 |
| AU2019378161A1 (en) | 2021-06-03 |
| SI3880678T1 (sl) | 2025-08-29 |
| EP3880678A4 (en) | 2022-08-31 |
| AU2019378161B2 (en) | 2025-01-30 |
| LT3880678T (lt) | 2025-06-25 |
| HRP20250864T1 (hr) | 2025-09-26 |
| EP3880678B1 (en) | 2025-05-07 |
| HUE071480T2 (hu) | 2025-08-28 |
| RS66922B1 (sr) | 2025-07-31 |
| WO2020099923A1 (en) | 2020-05-22 |
| FI3880678T3 (fi) | 2025-08-01 |
| IL282996A (en) | 2021-06-30 |
| US20220002292A1 (en) | 2022-01-06 |
| PL3880678T3 (pl) | 2025-08-04 |
| DK3880678T3 (da) | 2025-06-10 |
| JP2024153665A (ja) | 2024-10-29 |
| SMT202500237T1 (it) | 2025-07-22 |
| CA3119711A1 (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3033466T3 (en) | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate | |
| ES2900016T3 (es) | Una forma cristalina de un inhibidor de MAGL | |
| US6306436B1 (en) | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride | |
| CN107530348B (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| BR112021003655A2 (pt) | métodos novos | |
| KR101072909B1 (ko) | 경구고형의약 | |
| JP2010506846A (ja) | フェニルアルキルカルバメート組成物 | |
| US20120141586A1 (en) | Thrombin receptor antagonist and clopidogrel fixed dose tablet | |
| ES2901598T3 (es) | Comprimido recubierto con película que tiene una alta estabilidad química del ingrediente activo | |
| CN105407925A (zh) | 用于泡腾剂型的制造工艺 | |
| JP2017043546A (ja) | 感冒用医薬組成物 | |
| ES2908924T3 (es) | Composiciones orales sólidas de liberación lenta | |
| WO2006040779A2 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
| AU2006271150A1 (en) | Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor | |
| EP4268816B1 (en) | Oral solid preparation | |
| JP2021532183A (ja) | フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ | |
| US10117876B2 (en) | Pharmaceutical composition of fused aminodihydrothiazine derivative | |
| ES3033299T3 (en) | Crystalline forms of compounds for preventing or treating sensory hair cell death | |
| JP4393119B2 (ja) | ヨウ化イソプロパミド含有製剤 | |
| HK40099642A (en) | Oral solid preparation | |
| CN102440958A (zh) | 一种布洛芬钠脂质体固体制剂及其制法 | |
| JP2007297348A (ja) | エバスチンを含有する錠剤 | |
| HK1244704B (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| CN103301116A (zh) | 口服医药组合物 | |
| JP2011063567A (ja) | 保存安定性の向上した錠剤 |